86.02
Schlusskurs vom Vortag:
$86.97
Offen:
$86.7
24-Stunden-Volumen:
977.15K
Relative Volume:
0.93
Marktkapitalisierung:
$4.33B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-28.71
EPS:
-2.9966
Netto-Cashflow:
$-24.94M
1W Leistung:
+2.91%
1M Leistung:
+7.55%
6M Leistung:
+77.62%
1J Leistung:
+87.61%
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Vergleichen Sie SLNO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SLNO
Soleno Therapeutics Inc
|
86.02 | 4.41B | 0 | -38.99M | -24.94M | -2.9966 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-23 | Eingeleitet | TD Cowen | Buy |
2025-03-05 | Fortgesetzt | Stifel | Buy |
2024-12-02 | Bestätigt | Robert W. Baird | Outperform |
2024-12-02 | Bestätigt | Stifel | Buy |
2024-09-03 | Eingeleitet | H.C. Wainwright | Buy |
2024-05-10 | Eingeleitet | Robert W. Baird | Outperform |
2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
2024-01-23 | Eingeleitet | Stifel | Buy |
2023-11-21 | Fortgesetzt | Guggenheim | Buy |
2020-09-29 | Eingeleitet | Guggenheim | Buy |
2020-01-10 | Eingeleitet | Craig Hallum | Buy |
2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno Therapeutics Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
What analysts say about Soleno Therapeutics Inc. stockTremendous wealth creation - Autocar Professional
Is Soleno Therapeutics Inc. a good long term investmentConsistently high yield - jammulinksnews.com
What drives Soleno Therapeutics Inc. stock priceFast-track wealth growth - jammulinksnews.com
Soleno Therapeutics’ Vykat XR Exceeds Sales Expectations - Yahoo Finance
Soleno gains as Betaville cites buyout interest (update) - MSN
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics: A Strategic Capital Raise Balances M&A Optionality with Long-Term Growth Potential - AInvest
Soleno Therapeutics: Fairly Valued Despite M&A Expectations - Seeking Alpha
Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer - The Globe and Mail
Mintz Advises on Soleno Therapeutics’ $200 Million Public Offering - Mintz
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch - Investing.com Nigeria
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch By Investing.com - Investing.com South Africa
Soleno Therapeutics Announces Public Stock Offering - TipRanks
In Brief: Soleno To Raise $200m To Boost Vykat XR Launch - insights.citeline.com
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales - Investing.com Australia
Soleno Therapeutics prices $200M public offering - MSN
Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales By Investing.com - Investing.com South Africa
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewswire
Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales - Investing.com Nigeria
Firm Advises Soleno Therapeutics on $200 Million Public Offering - Wilson Sonsini
Soleno reports preliminary Q2 revenue of $31-33 million for VYKAT XR - Investing.com Nigeria
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Soleno sales of new Prader-Willi drug rise faster than expected - BioPharma Dive
Soleno Therapeutics Prices $200 Mln Public Offering To Support VYKAT XR Launch - Nasdaq
Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com - Investing.com Canada
Soleno Therapeutics stock falls after pricing $200 million offering - Investing.com
Soleno Therapeutics prices public offering at $85 per share - Investing.com
Soleno Therapeutics prices public offering at $85 per share By Investing.com - Investing.com South Africa
Soleno Therapeutics Secures $200M Public Offering to Commercialize Breakthrough Prader-Willi Treatment - Stock Titan
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales By Investing.com - Investing.com South Africa
Soleno Therapeutics: Q2 2025 Results Signal Breakout Potential in Rare Disease Market - AInvest
Soleno Therapeutics announces preliminary financial and operational results for Q2 - MarketScreener
Soleno Therapeutics' $200M Secondary Offering: Catalyst for Growth or Dilution Danger Zone? - AInvest
Soleno Therapeutics Reports Q2 Preliminary Net Revenue - MarketScreener
Soleno Therapeutics Proposes $200 Million Public Offering - MarketScreener
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):